Hangzhou RonGu Biotechnology Co., Ltd. (“RonGu Biotechnology”) announced the completion of a Series A financing of nearly RMB 100 million. The round was jointly participated by Changjin Holdings, Yichen Investment, Hangzhou Jingya, and Shaoxing Jingteng. The proceeds will be used to support the company in advancing IND filings for its single‑target and dual‑target pipelines in systemic lupus erythematosus (SLE), as well as the clinical translation of new medical technologies.
Financing Milestone
| Item | Detail |
|---|---|
| Company | Hangzhou RonGu Biotechnology Co., Ltd. |
| Round | Series A |
| Amount | Nearly RMB 100 million |
| Investors | Changjin Holdings, Yichen Investment, Hangzhou Jingya, Shaoxing Jingteng |
| Announcement Date | 9 Nov 2026 |
| Use of Proceeds | IND filings for single‑target and dual‑target SLE pipelines; clinical translation of new medical technologies |
| Valuation | Not disclosed |
Company Profile & Technology Platforms
- Founding & Focus: Founded in 2018, RonGu Biotechnology focuses on the R&D and industrialization of umbilical cord blood‑derived off‑the‑shelf universal CAR‑NK and CAR‑T cell therapies.
- Proprietary Platforms: The company has established underlying technology platforms encompassing high‑efficiency lentiviral vector transduction, high‑efficiency immune cell expansion processes, and high‑throughput nanobody screening.
- Therapeutic Areas: Focus on the treatment of autoimmune diseases, while also advancing programs in hematologic malignancies and solid tumors.
- Clinical Progress: The company has achieved encouraging clinical efficacy in the treatment of SLE and B‑cell lymphoma.
Industry Context – Off‑the‑Shelf Cell Therapy
- Umbilical Cord Blood Source: Cord blood‑derived CAR‑NK and CAR‑T cells offer a renewable starting material for “universal,” off‑the‑shelf products, addressing the cost, delay, and manufacturing variability of autologous therapies.
- Autoimmune Indications: Cell therapy for autoimmune diseases – led by systemic lupus erythematosus (SLE) – has emerged as one of the most active frontiers following encouraging results with B‑cell–targeted approaches.
- Dual‑Target Design: Single‑ and dual‑target constructs aim to deepen B‑cell depletion or broaden mechanism coverage, potentially improving durability of response in refractory autoimmune disease.
Market Impact & Outlook
- Regulatory Inflection Point: Proceeds are earmarked for IND filings across the single‑target and dual‑target SLE pipelines, moving the company toward formal clinical development of its universal cell therapies.
- Manufacturing Scalability: The off‑the‑shelf model, supported by high‑efficiency transduction and expansion platforms, positions RonGu for industrialized, batch‑manufactured cell therapy supply.
- Investor Syndicate: Participation by four institutional investors – Changjin Holdings, Yichen Investment, Hangzhou Jingya, and Shaoxing Jingteng – reflects regional and healthcare‑focused capital backing for the autoimmune cell therapy sector.
- Financial Impact: The transaction is a private financing; no valuation or revenue figures were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding RonGu Biotechnology’s use of Series A proceeds, IND filings for its SLE pipelines, clinical translation of new medical technologies, and pipeline advancement in autoimmune diseases and oncology. Actual results may differ due to risks including regulatory review outcomes, clinical trial results, manufacturing scale‑up, competitive dynamics in cell therapy, and access to future financing.-Fineline Info & Tech
